Feb 24, 2009 - Winston Pharmaceuticals, Inc. today announced that it has received orphan drug designation from the U.S. FDA for its lead compound, Civamide, a novel TRPV-1 receptor modulator, being developed as a dermal patch for the treatment of post-herpetic neuralgia.
The details can be read here.
No comments:
Post a Comment